Global Thyroid Eye Disease (TED) Clinical Landscape Market Report 2021: Marketed and Pipeline Drugs, Trials, Key Events, Probability Of Success, 10-Year Disease Prevalence Forecast, Deals, Revenue – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Thyroid Eye Disease (TED)” report has been added to ResearchAndMarkets.com’s offering.

Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues.

It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.

Key Takeaways

• Thyroid eye disease (TED) is associated with thyroid disease, and most commonly occurs in Graves’ disease, where it is estimated to be present in ~40% of patients.
• Epidemiological data are limited for TED, but it is reported in the literature that the annual incidence of TED in the general population is 16 per 100,000 in women and three per 100,000 in men.
• Based on these rates, the publisher estimates that in 2020, there were 384,000 incident cases of TED worldwide, and expects that number to increase to 438,000 incident cases by 2029.
• The only approved drug in the TED space is Horizon’s Tepezza, which targets insulin-like growth factor-1 receptor. It is currently available as an intravenous formulation.
• The only industry-sponsored drug in active clinical development for TED is in Phase II.
• The only drug in development for TED targets Fc neonatal receptor. It is administered via the subcutaneous route.
• The only high-impact upcoming event in the TED space is top-line results from Tepezza’s Chronic TED trial. The overall likelihood of approval of a Phase I ophthalmology-other asset is 24.7%, and the average probability a drug advances from Phase III is 59.5%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.
• Clinical trials for TED are equally distributed between the mid and late phases of development.
• Horizon Therapeutics has the highest number of ongoing clinical trials for TED, with two trials.
• Horizon Therapeutics leads industry sponsors with the highest overall number of clinical trials for TED

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Definition
• Patient segmentation
• Symptoms
• Risk factors
• Diagnosis

TREATMENT

• Medical treatment
• Orbital radiotherapy
• Surgical treatment

EPIDEMIOLOGY

• Thyroid eye disease occurrence in thyroid disorders
• Incidence methodology

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• IMVT-1401 for Thyroid Eye Disease (March 30, 2020)
• Tepezza for Thyroid Eye Disease (December 13, 2019)
• Tepezza for Thyroid Eye Disease (December 11, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

• Horizon Sees Blockbuster Future for Tepezza After US Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• MiRagen Acquires Viridian in All-Stock Deal

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent events

BIBLIOGRAPHY

• Prescription information

APPENDIX

LIST OF FIGURES

• Figure 1: Trends in incident cases of thyroid eye disease, 2020-29
• Figure 2: Overview of pipeline drugs for thyroid eye disease in the US
• Figure 3: Pipeline drugs for thyroid eye disease, by company
• Figure 4: Pipeline drugs for thyroid eye disease, by drug type
• Figure 5: Pipeline drugs for thyroid eye disease, by classification
• Figure 6: IMVT-1401 for Thyroid Eye Disease (March 30, 2020): Phase IIa – ASCEND-GO 1
• Figure 7: Key upcoming events in thyroid eye disease
• Figure 8: Probability of success in the ophthalmology-other pipeline
• Figure 9: Clinical trials in thyroid eye disease
• Figure 10: Top 10 drugs for clinical trials in thyroid eye disease
• Figure 11: Top 10 companies for clinical trials in thyroid eye disease
• Figure 12: Thyroid eye disease trials status
• Figure 13: Thyroid eye disease trials sponsors, by phase

LIST OF TABLES

• Table 1: Prevalence of thyroid eye disease in Graves’ disease
• Table 2: Incident cases of thyroid eye disease, 2020-29
• Table 3: Marketed drugs for thyroid eye disease
• Table 4: Pipeline drugs for thyroid eye disease in the US
• Table 5: IMVT-1401 for Thyroid Eye Disease (March 30, 2020)
• Table 6: Tepezza for Thyroid Eye Disease (December 13, 2019)
• Table 7: Tepezza for Thyroid Eye Disease (December 11, 2019)
• Table 8: Forecasted global sales, by drug ($m), 2021-25

   

   

For more information about this report visit https://www.researchandmarkets.com/r/15phkx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900